Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
Xiao-Ying Zhao,1 Hui-Min Xu,2 Quan Zhou2 1The Medical Ethics Committee, 2Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of ChinaWe read with great interest the study by Del Tacca et al,1 who perf...
Main Authors: | Zhao XY, Xu HM, Zhou Q |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-11-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/sampling-times-and-genotyping-concerns-in-bioequivalence-evaluation-of-a15075 |
Similar Items
-
Evaluation of Bioequivalence of Generic Imatinib Products and Generic Tacrolimus Products Based on Indirect Comparison of the Results of Their Bioequivalence Studies
by: D. V. Goryachev, et al.
Published: (2019-09-01) -
Planning and Evaluation of Bioequivalence Studies of Telmisartan Generic Drug Products
by: A. L. Khokhlov, et al.
Published: (2019-09-01) -
Generic Drug Product Development Bioequivalence Issues
by: Iain J. McGilveray
Published: (2008-08-01) -
Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions
by: Wang MN, et al.
Published: (2021-01-01) -
Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers
by: Ani Isnawati, et al.
Published: (2018-08-01)